Douglas Ward

4.2k total citations
44 papers, 3.0k citations indexed

About

Douglas Ward is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Douglas Ward has authored 44 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Infectious Diseases, 34 papers in Virology and 19 papers in Emergency Medicine. Recurrent topics in Douglas Ward's work include HIV/AIDS drug development and treatment (35 papers), HIV Research and Treatment (34 papers) and HIV-related health complications and treatments (19 papers). Douglas Ward is often cited by papers focused on HIV/AIDS drug development and treatment (35 papers), HIV Research and Treatment (34 papers) and HIV-related health complications and treatments (19 papers). Douglas Ward collaborates with scholars based in United States, United Kingdom and Canada. Douglas Ward's co-authors include Scott D. Holmberg, Anne C. Moorman, Kathleen C. Wood, Frank J. Palella, Benjamin Young, Kathy Wood, Alan E. Greenberg, Tony C. Tong, John Williamson and Robert S. Janssen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Gastroenterology.

In The Last Decade

Douglas Ward

44 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas Ward United States	23	2.1k	1.7k	1.4k	537	206	44	3.0k
Clifford Leen United Kingdom	31	1.7k 0.8×	1.1k 0.6×	751 0.5×	1.1k 2.1×	291 1.4×	117	2.8k
G. Filice Italy	25	1.2k 0.6×	716 0.4×	578 0.4×	1.6k 2.9×	168 0.8×	96	3.0k
Joan Romeu Spain	26	1.6k 0.8×	1.4k 0.8×	532 0.4×	524 1.0×	221 1.1×	67	2.3k
Andrzej Horban Poland	34	2.1k 1.0×	1.2k 0.7×	504 0.4×	2.4k 4.6×	280 1.4×	183	4.6k
Alessandro Cozzi‐Lepri United Kingdom	32	2.0k 0.9×	1.8k 1.1×	813 0.6×	742 1.4×	245 1.2×	90	2.9k
Johan N. Bruun Norway	22	1.1k 0.5×	773 0.5×	490 0.3×	692 1.3×	356 1.7×	75	2.3k
Juan González‐Lahoz Spain	40	2.6k 1.2×	1.7k 1.0×	726 0.5×	2.3k 4.2×	391 1.9×	172	4.9k
Pompeyo Viciana Spain	31	1.7k 0.8×	1.2k 0.7×	408 0.3×	1.1k 2.0×	403 2.0×	131	2.9k
Adrián Curran Spain	26	972 0.5×	733 0.4×	423 0.3×	713 1.3×	167 0.8×	126	1.8k
Juan González‐García Spain	27	1.7k 0.8×	790 0.5×	660 0.5×	1.9k 3.4×	218 1.1×	165	3.5k

Countries citing papers authored by Douglas Ward

Since Specialization

Citations

This map shows the geographic impact of Douglas Ward's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Ward with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Ward more than expected).

Fields of papers citing papers by Douglas Ward

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Ward. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Ward. The network helps show where Douglas Ward may publish in the future.

Co-authorship network of co-authors of Douglas Ward

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Ward. A scholar is included among the top collaborators of Douglas Ward based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Ward. Douglas Ward is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brar, Indira, Peter Ruane, Douglas Ward, et al.. (2020). 1028. Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine. Open Forum Infectious Diseases. 7(Supplement_1). S543–S544. 3 indexed citations

Davis, Wendy, Andrea Mantsios, Tahilin Sanchez Karver, et al.. (2020). “It made me more confident that I have it under control”: Patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain. PLoS ONE. 15(5). e0232473–e0232473. 8 indexed citations

Ward, Douglas, Moti Ramgopal, David J. Riedel, et al.. (2019). 2485. Real-world Experience with Dolutegravir Plus Rilpivirine Two-Drug Regimen. Open Forum Infectious Diseases. 6(Supplement_2). S861–S861. 1 indexed citations

Sax, Paul E., Edwin DeJesus, Gordon Crofoot, et al.. (2018). Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide. AIDS. 32(12). 1723–1725. 7 indexed citations

Aberg, Judith A., et al.. (2017). Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. The Lancet HIV. 4(7). e284–e294. 61 indexed citations

Ross, Lisa, Joseph Horton, Samiul Hasan, et al.. (2014). HIV-1 Transmission Patterns in Antiretroviral Therapy-Naïve, HIV-Infected North Americans Based on Phylogenetic Analysis by Population Level and Ultra-Deep DNA Sequencing. PLoS ONE. 9(2). e89611–e89611. 4 indexed citations

Squires, Kathleen, Benjamin Young, Edwin DeJesus, et al.. (2012). ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine. HIV Clinical Trials. 13(5). 233–244. 21 indexed citations

Walmsley, Sharon, Anchalee Avihingsanon, Jihad Slim, et al.. (2009). Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes. 50(4). 367–374. 76 indexed citations

DeJesus, Edwin, Benjamin Young, Javier O Morales-Ramirez, et al.. (2009). Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 51(2). 163–174. 108 indexed citations

10.

Angel, Jonathan B., Wayne Greaves, Jianmin Long, et al.. (2009). Virologic and immunologic activity of PegIntron in HIV disease. AIDS. 23(18). 2431–2438. 4 indexed citations

11.

Elion, Richard, Calvin Cohen, Douglas Ward, et al.. (2008). Evaluation of Efficacy, Safety, Pharmacokinetics, and Adherence in HIV-1—Infected, Antiretroviral-Naïve Patients Treated with Ritonavir-Boosted Atazanavir Plus Fixed-Dose Tenofovir DF/Emtricitabine Given Once Daily. HIV Clinical Trials. 9(4). 213–224. 22 indexed citations

12.

Lalezari, Jacob, et al.. (2007). Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006. Journal of Antimicrobial Chemotherapy. 60(1). 170–174. 6 indexed citations

13.

Walmsley, Sharon, Laurent Cotte, Stefano Rusconi, et al.. (2007). Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores. AIDS. 21(16). 2245–2248. 8 indexed citations

14.

Ward, Douglas, et al.. (2006). Switch from Efavirenz to Nevirapine Associated with Resolution of Efavirenz-Related Neuropsychiatric Adverse Events and Improvement in Lipid Profiles. AIDS Patient Care and STDs. 20(8). 542–548. 41 indexed citations

15.

Ruane, Peter, Edwin DeJesus, Daniel S Berger, et al.. (2006). Pilot Study of Once-Daily Simplification Therapy with Abacavir/Lamivudine/Zidovudine and Efavirenz for Treatment of HIV-1 Infection. HIV Clinical Trials. 7(5). 229–236. 8 indexed citations

16.

Lonergan, J Tyler, Grace A. McComsey, Robin L. Fisher, et al.. (2004). Lack of Recurrence of Hyperlactatemia in HIV-Infected Patients Switched From Stavudine to Abacavir or Zidovudine. JAIDS Journal of Acquired Immune Deficiency Syndromes. 36(4). 935–942. 15 indexed citations

17.

Lichtenstein, Kenneth, Carl Armon, Douglas Ward, et al.. (2003). Incidence of and Risk Factors for Lipoatrophy (Abnormal Fat Loss) in Ambulatory HIV-1-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 32(1). 48–56. 161 indexed citations

18.

Dybul, Mark, Tae‐Wook Chun, Douglas Ward, et al.. (2000). Evaluation of Lymph Node Virus Burden in Human Immunodeficiency Virus–Infected Patients Receiving Efavirenz‐Based Protease Inhibitor–Sparing Highly Active Antiretroviral Therapy. The Journal of Infectious Diseases. 181(4). 1273–1279. 22 indexed citations

19.

Kuritzkes, Daniel R., et al.. (1998). Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection. AIDS. 12(1). 65–74. 66 indexed citations

20.

Ungar, B L, et al.. (1990). Cessation of Cryptosporidium-associated diarrhea in an acquired immunodeficiency syndrome patient after treatment with hyperimmune bovine colostrum. Gastroenterology. 98(2). 486–489. 144 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact